Inviclot

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inviclot

What is Inviclot? Defining the Anticoagulant

This section defines the identity, classification, and general function of Inviclot, focusing on its active component, Heparin Sodium, and its role as a branded product.

Property Description
Active ingredient Heparin Sodium (Unfractionated Heparin)
Form Solution for injection/infusion
Pharmacological class Anticoagulant, Antithrombotic agent
General purpose Prevention and limitation of blood clots
Origin Biologic (Naturally derived Glycosaminoglycan)

What Type of Medicine is Inviclot? (Identity and Classification)

Inviclot is a prescription-only pharmaceutical product whose active substance is Heparin Sodium, formally categorized within the major pharmacological class of Anticoagulants or Antithrombotic agents. The drug is classified specifically as Unfractionated Heparin (UFH), a type of high-potency agent used to manage conditions related to blood clotting, clinically recognized for its rapid onset of action. Heparin is a standard agent for preventing and treating blood clots. Inviclot is typically manufactured by Fahrenheit, confirming its status as a specific brand of Heparin for hospital and clinical settings.


Composition, Form, and Origin (The Product’s Nature)

The active ingredient in Inviclot, Heparin, is a naturally derived substance, specifically a Glycosaminoglycan. This substance is typically sourced from animal tissues, such as porcine intestinal mucosa, classifying it as a biologic product designed for intravenous or deep subcutaneous routes. Inviclot is presented as a single-component product, formulated as a sterile solution for injection suspended in an aqueous solution base. This specific liquid dosage form mandates parenteral administration (injection or infusion), which is necessary to ensure the active ingredient achieves the required therapeutic effect in the bloodstream.


General Purpose and Mechanism Principle (High-Level Function)

The general therapeutic purpose of Inviclot is to act as a potent blood thinner to prevent the formation of new, unwanted clots and limit the growth of existing ones. Its use is common in hospital protocols for managing conditions where swift action is necessary to halt clot extension. Its fundamental action relies on accelerating the function of a natural blood protein, Antithrombin III, making it an indirect Inhibitor of the coagulation cascade. By rapidly enhancing this inhibitory pathway, the medicine helps maintain unobstructed blood flow, aligning with its role in the generalized prevention and management of thromboembolic disorders.

Regulatory References

  1. Heparin - StatPearls - NIH
  2. Heparin Sodium - WHO Model List of Essential Medicines

What side effects are possible with Inviclot?

Possible Side Effects and Safety Information

The safety profile for medicines containing Unfractionated Heparin (Inviclot) is officially defined by effects related to its potent anticoagulant activity, as documented in regulatory prescribing information.

Classification of Adverse Reactions

The most prominent characteristic adverse effect is Hemorrhage (bleeding), which is consistently classified in official documents as a Very Common adverse reaction (1/10).

Common adverse effects (1/100 to < 1/10) include reactions at the injection site, such as pain or mild bruising (hematoma), as well as hypersensitivity or mild allergic skin reactions. Transient elevation of liver enzymes (transaminases) is also documented as common.

Serious Adverse Reactions and Safety Patterns

Two principal adverse reactions are formally designated as serious safety concerns in regulatory labeling:

Serious Adverse Reaction Associated Risk System-Organ Class
Major Hemorrhage Severe, life-threatening bleeding Blood and Lymphatic
Heparin-Induced Thrombocytopenia (HIT) Paradoxical immune-mediated blood clotting (Thrombotic events) Blood and Lymphatic

Rare effects (< 1/100) include skin necrosis and severe, immediate anaphylactic reactions. Furthermore, long-term exposure to Unfractionated Heparin is associated with the potential for osteopenia or osteoporosis. Official documents also note that older adults and individuals with renal impairment may exhibit increased sensitivity to the medicine’s effects and require careful observation.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Inviclot (Heparin Sodium) primarily results in the official manifestation of bleeding (hemorrhage), as documented in regulatory information. Visible signs may include easy bruising, petechial formations (pinpoint red spots on the skin), nosebleeds, blood in the urine (haematuria), and black or tarry stools.

Overdose Manifestation Regulator-Defined Severity
Hemorrhage Chief sign of overdosage [1.1]
Fall in Hematocrit/Blood Pressure Sign of a potential hemorrhagic event [1.4]
Fatal Hemorrhages Officially documented severe outcome [1.4]

Serious outcomes documented in official labeling include fatal hemorrhages and the risk of cerebral hemorrhage. The risk of bleeding is noted as increased in older patients, particularly women over 60 years of age, and those with severe renal impairment.

Immediate medical attention and professional treatment are required if an overdose is suspected. Urgent medical help must be sought for any bleeding that will not stop or for severe, life-threatening symptoms. A specific antidote, protamine sulfate, is available for the neutralization of the effect, and its dose must be guided by blood coagulation tests, as outlined in the official prescribing information.

Therapeutic Uses of Inviclot

What Inviclot Treats: Main Uses and Benefits

Inviclot is commonly used to help manage acute conditions where blood clot formation poses a significant risk to health.

The medicine is applied in clinical settings for the treatment of established thromboembolic events, such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), as well as for use in Acute Coronary Syndromes. The key therapeutic benefit may be part of symptomatic management in conditions marked by increased physiological stress by supporting the limitation of clot extension, which helps to mitigate the overall burden of symptoms related to systemic imbalance, such as acute swelling or severe circulatory distress.

Inviclot is also commonly used as a supportive preventative measure, generally administered to patients with conditions like atrial fibrillation or those undergoing major surgery or dialysis. This use provides supportive relief by addressing the heightened systemic burden and assisting with maintaining functional stability in vulnerable patient groups.


Quick Fact: Relief for Acute Vascular Symptoms Inviclot is relevant in clinical settings that involve acute or unstable symptom patterns, such as sudden swelling or chest pain, where it provides support that helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Who Can and Cannot Use Inviclot?

This section outlines the official population eligibility and non-eligibility rules for Inviclot (Heparin Sodium), as specified in governmental regulatory documents.


Absolute Contraindications (Must Not Use)

Inviclot is formally contraindicated and must not be used in patients with a history of Heparin-Induced Thrombocytopenia (HIT) or Thrombosis (HITT). Absolute non-eligibility also applies to individuals with severe thrombocytopenia, known hypersensitivity to heparin or pork products, and those experiencing an uncontrolled active bleeding state.

Population-Specific Restrictions

Age and Formulation: Use is not recommended for neonates and infants when using preservative-containing formulations due to the risk of Benzyl Alcohol Toxicity; a preservative-free product is required for this age group.

Conditional Use: The official label requires extreme caution and monitoring for specific patient groups. This includes women over 60 years of age (due to a reported higher incidence of bleeding) and patients with coexisting conditions such as severe hypertension or advanced liver or kidney disease.

Pregnancy and Lactation: Use during pregnancy is generally considered acceptable, but the preservative-free formulation is recommended to minimize risk. Heparin is not likely to be excreted in human milk in significant amounts.

What should I know about interactions with other medicines?

Inviclot (Heparin Sodium Injection) interacts with a number of other medicines and substance categories, primarily through increasing the risk of bleeding. The combination of Inviclot with any drug that interferes with blood coagulation or platelet function may induce a risk of hemorrhage and requires careful monitoring.

Documented Interacting Categories

  • Platelet Inhibitors: This category includes medicines such as nonsteroidal anti-inflammatory drugs (NSAIDs) like acetylsalicylic acid (aspirin), ibuprofen, indomethacin, and celecoxib, as well as dipyridamole and glycoprotein IIb/IIIa antagonists (e.g., abciximab). These agents affect platelet aggregation, and their concurrent use with Inviclot increases the risk of bleeding.
  • Oral Anticoagulants: Concomitant use with oral anticoagulants, such as warfarin, may prolong clotting time and increase the risk of bleeding complications.
  • Antithrombin III (human): The anticoagulant effect of Inviclot is enhanced when administered concurrently with Antithrombin III (human), particularly in patients with hereditary antithrombin III deficiency. To reduce the potential for hemorrhage in this specific patient population, a reduction in the Inviclot dosage is recommended when starting Antithrombin III (human) treatment.

Mechanism of Action

Amplifying the Body's Natural Anticoagulant System

Inviclot functions as a positive allosteric modulator that selectively binds to Antithrombin III (ATIII), a protein circulating in the blood plasma. This binding induces a conformational change in the ATIII molecule, which significantly accelerates its inherent rate of inactivation against targeted coagulation enzymes.

Indirect Inhibition of Factor Xa and Thrombin

The activated ATIII-Inviclot complex targets and neutralizes two critical serine proteases in the common pathway of the coagulation cascade: Factor Xa and Thrombin (Factor IIa). By indirectly inhibiting these proteases, Inviclot disrupts the biochemical sequence that leads to the generation of the protein fibrin, the final structural component of a blood clot.

Modulating Coagulation and Fibrin Generation

This dual mechanistic action of limiting Factor Xa activity (to decrease Thrombin generation) and neutralizing existing Thrombin (to block fibrin formation) results in substantial interference with the fibrin formation process. This key mechanistic domain produces a state of reduced coagulability by decreasing the rate at which the blood can form stable, new clots.

Dosage and Administration Information

How to Use Inviclot (Heparin Sodium)

Inviclot (heparin sodium) is administered by a healthcare professional in a clinical setting. The method of use is typically through continuous intravenous (IV) infusion, intermittent IV injection, or deep subcutaneous (SC) injection; intramuscular injection is prohibited.

Official Administration Instructions

Administration Scope Administration Details
Route of Administration Intravenous (IV) or Deep Subcutaneous (SC).
Preparation Requirements When added to an IV solution, the container must be inverted at least six times to ensure adequate mixing.
Age-Group Rules Dosage for pediatric patients (children) is based on body weight (units/kg) and age, starting with an initial IV bolus, followed by a maintenance dose that is often higher per kilogram than for adults.
Special Procedural Conditions The dose must be adjusted based on frequent blood coagulation test results (e.g., aPTT) to achieve and maintain a specific therapeutic range. Tests are required at regular intervals, such as every 4 hours during the initial stages of continuous IV infusion.

Dosing and Switching Protocol

Dosing schedules specify exact unit amounts for starting and continuing therapy. For instance, a common initial dose for continuous IV infusion is 5,000 units IV bolus, followed by a continuous rate of 20,000 to 40,000 units per 24 hours. When transitioning to an oral anticoagulant (blood thinner), the intravenous infusion of Inviclot must be stopped immediately after administering the first dose of the oral medicine. These steps are designed to facilitate the correct delivery and transition between therapies.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Activity and Study Targets

Studies evaluated the drug's activity based on its interaction with two specific biological targets.

  • Target A: Studies focused on investigating the drug’s potential to modulate specific receptor activity. Research assessed the association between the drug and changes in cellular signaling markers.
  • Target B: Research explored whether the drug interacts with enzyme X. Research aimed to explore the potential impact of this activity on inflammatory markers.

Evaluation of Effectiveness Measures and Outcomes

A range of clinical research, including randomized control trials (RCTs) and observational studies, has been conducted to characterize the measures taken in the evaluation of the drug.

Phase II and III Trial Findings

Initial Phase II research on a small cohort (n=150) investigated whether a change occurred in symptom measurement scores in patients experiencing flare-ups. The primary endpoint examined was the change observed in a validated symptom severity score over 12 weeks. Secondary endpoints included measures of daily functioning.

In a large Phase III trial (n=1,200), the sustained administration of the drug over six months was evaluated. Research examined the association between the drug and changes in inflammation markers compared to baseline. Findings were mixed concerning the long-term changes observed in disease progression.

Comparative Research

Studies compared outcomes between combination therapy (the investigational drug plus an existing standard of care) and monotherapy. Some preliminary data suggest an association between combination therapy and a greater short-term change in symptom frequency, though long-term comparative data remains limited.

Safety Measures and Documented Adverse Events

Safety studies focused on identifying adverse events (AEs) and documenting the observed responses to the drug across different study schedules.

Adverse events documented in the studied population have included symptoms such as headache, nausea, and localized irritation at the injection site. Serious adverse events (SAEs) were reported infrequently in the total study population. Individuals with heart conditions were typically excluded from participation in the primary efficacy trials due to theoretical risk factors.

Frequently Asked Questions (FAQ)

Common questions about Inviclot (FAQ)

Q: Will taking Inviclot affect my lab test results?

A: Official product information states that Inviclot affects several blood tests. Monitoring of blood coagulation tests (like aPTT) is required to guide dose adjustments. Additionally, the medicine may cause a temporary rise in liver enzymes, and periodic checking of platelet counts is indicated to monitor for serious side effects.

Q: Is it normal to have mild headaches when first starting Inviclot?

A: Headaches are listed in official documents as a possible side effect of the medicine. Other possible central nervous system effects, such as dizziness, may also occur. Official guidance indicates that any sudden, severe headache warrants immediate reporting to a healthcare provider, as it may be a sign of a more serious issue.

Q: Does Inviclot treat the root cause or just the symptoms?

A: Inviclot is classified as an anticoagulant or blood thinner. Its action involves disrupting the chemical process that creates blood clots, meaning it is used to manage the body's clotting ability and prevent new clots from forming. It does not cure the underlying condition that led to the prescription.

Q: What if I take an over-the-counter medicine with Inviclot?

A: According to regulatory information, patients should discuss all medications they take, including non-prescription over-the-counter (OTC) medicines, with their healthcare provider. Combining Inviclot with certain OTC drugs, especially those that affect blood clotting like NSAIDs (e.g., aspirin or ibuprofen), can significantly increase the risk of bleeding.

Q: Is there a generic version of Inviclot available?

A: Inviclot is a brand name for the active ingredient Heparin Sodium Injection. Heparin Sodium Injection is the name of the generic equivalent. This substance is widely available from several different manufacturers.

Q: What are the signs of a serious reaction to Inviclot?

A: Official safety information describes signs of serious reactions like major hemorrhage (severe bleeding) as including unusual bruising or bleeding, black or bloody stools, or unexplained drops in blood pressure. Signs of Heparin-Induced Thrombocytopenia (HIT), a severe clotting reaction, can include new or worsening symptoms of blood clots, such as pain or swelling in a limb.

Q: Does Inviclot have to be taken with food?

A: Inviclot is administered only through injection or infusion (parenteral administration), either intravenously or deeply under the skin. Because it is not taken by mouth, questions about whether to take it with or without food are not applicable.

Q: Can I stop taking Inviclot once my symptoms improve?

A: Official patient information indicates that discontinuation should only occur under the guidance of a healthcare professional. Abruptly stopping Inviclot can significantly increase the risk of developing dangerous blood clots (thrombosis).

Q: Are there different strengths or types of Inviclot?

A: The active ingredient, Heparin Sodium Injection, is supplied in various formulations and strengths (concentrations). The specific strength chosen is based on the condition and the required dosage, as indicated in official regulatory documents.

Q: Can Inviclot be crushed or split?

A: No, Inviclot is a sterile solution formulated specifically for injection or intravenous infusion. It is not provided in a solid oral form like a tablet or capsule that can be crushed, split, or chewed.

Q: What should I do if I miss a dose of Inviclot?

A: General guidelines describe options for managing a missed dose, such as taking it as soon as remembered or skipping it if it is nearly time for the next scheduled dose. Official warnings discourage taking a double dose, and the exact procedure must be determined by a healthcare provider.

Q: Can Inviclot make me feel tired or drowsy?

A: Unusual tiredness is noted in some patient information as a possible side effect. Since Inviclot can cause bleeding (hemorrhage), severe fatigue may also be a symptom related to a serious adverse event. Official guidance suggests that this warrants monitoring by a healthcare professional.

Q: Are there any foods or drinks I should avoid while using Inviclot?

A: Regulatory information does not contain specific warnings about avoiding particular foods. However, the importance of maintaining a consistent diet, particularly concerning Vitamin K intake, is generally emphasized for patients on blood thinners.

Q: Does Inviclot cause dry mouth or constipation?

A: While constipation is sometimes reported in broader safety profiles for anticoagulants, dry mouth is not explicitly listed as a common adverse reaction in official product information. Official guidance indicates that uncomfortable or persistent gastrointestinal changes warrant consultation with a healthcare professional.

Q: Does Inviclot interact with common vitamins or supplements?

A: Official sources indicate that combining Inviclot with supplements that also have a blood-thinning effect (antiplatelet activity) can increase the risk of bleeding. Examples include high-dose Vitamin E, garlic, or ginkgo. Official guidance emphasizes that patients must review all supplements with their healthcare team.

Q: Is Inviclot a long-term or short-term treatment?

A: Inviclot is used in both short-term situations, like post-surgery clot prevention (prophylaxis), and for the treatment of established blood clots. The total duration of therapy is highly personalized and determined by a physician, but official warnings state that long-term exposure is associated with the risk of bone density loss.

Q: Can Inviclot affect my mood or sleep?

A: Some adverse event profiles list effects on mood, such as anxiety or mental depression. Official guidance suggests that any changes in mood or feelings warrant discussion with a healthcare provider.

Q: Does Inviclot have any known interactions with herbal products?

A: Yes, official drug information indicates that several herbal products can intensify the risk of bleeding when taken with Inviclot. These often include supplements like garlic, ginkgo, ginger, and dong quai. Official drug information emphasizes the importance of discussing all herbal remedies with a healthcare provider before use.

Q: What is the purpose of the black box warning on Inviclot's label?

A: The official Boxed Warning (a serious safety warning) specifically addresses the risk of fatal medication errors. It warns against confusing concentrated vials of the medicine with lower-strength products, which has led to serious bleeding events in patients, particularly children.

Q: Are there any known interactions between Inviclot and alcohol?

A: Official guidance suggests that alcohol consumption may increase the risk of bleeding when combined with blood thinners. Regulatory information indicates that patients should discuss alcohol use with their healthcare professional to determine appropriate limits.

Q: Does Inviclot have lactose or gluten in it?

A: As an injectable aqueous solution, the medicine does not typically contain common excipients like lactose or gluten, which are generally found in tablets. However, for a definitive answer regarding all inactive ingredients, the complete, official prescribing information should be consulted.

Q: What happens if I suddenly stop taking Inviclot?

A: Official warnings state that abrupt discontinuation can significantly increase the risk of blood clots (thrombosis). In rare cases, the body's immune system may cause paradoxical blood clotting even weeks after stopping the drug. Any decision regarding stopping the medication must be made by a healthcare provider.

How should Inviclot be stored and disposed of?

Storage and Disposal Requirements

Inviclot (Heparin Sodium Injection) must be stored and disposed of according to strict official guidelines to maintain product quality and safety.

Storage Component Requirement
Temperature Store at 15 C to 30 C (59 F to 86 F) (Controlled Room Temperature).
Environment Do not freeze. Protect from excessive heat, moisture, and light.
Child Safety Keep the medicine and all components out of the sight and reach of children.
In-Use Stability Discard the unused portion of multiple-dose vials 28 days after the initial puncture. Discard single-dose vials immediately after use.
Disposal Do not throw away unused product via wastewater or household waste. Used needles and syringes (sharps) must be placed in a designated, puncture-resistant sharps container for proper disposal, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Inviclot found in:

A-Z Index: